Advances in Current Diabetes Proteomics: From the Perspectives of Label-free Quantification and Biomarker Selection.

Due to its prevalence and negative impacts on both economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification proteomics (LFQ) and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel protein biomarkers, and discover innovative therapeutic protein targets.

The purpose of this manuscript is to review and analyze the recent computational advances and development of label-free quantification and diabetic marker selection in diabetes proteomics.Web of Science database, PubMed database and Google Scholar were utilized for searching label-free quantification, computational advances, feature selection and diabetes proteomics.In this study, we systematically review the computational advances of label-free quantification and diabetic marker selection which be applied to get understanding of DM pathological mechanisms.

Firstly, different popular quantification measurements and proteomic quantification tools which have been applied to the diabetes studies are comprehensively discussed. Secondly, a number of popular manipulation methods including transformation, pretreatment (centering, scaling, and normalization), missing value imputation methods and a variety of popular feature selection techniques applied to diabetes proteomic data are overviewed with objective evaluation on their advantages and disadvantage.

UCPH-101
HY-10914 100mg
EUR 2184

ULK-101
HY-114490 10mg
EUR 911

JI-101
HY-16265 10mM/1mL
EUR 248

GlyH-101
HY-18336 10mg
EUR 223

MG-101
HY-18964 50mg
EUR 601

AT-101
A3196-10 10 mg
EUR 171
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1].

AT-101
A3196-50 50 mg
EUR 432
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1].

Sulforhodamine 101
80101 500MG
EUR 236
Description: Minimum order quantity: 1 unit of 500MG

UFP-101
B5128-1 1 mg
EUR 583

LOXO-101
B6176-100 100 mg
EUR 696
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival.

LOXO-101
B6176-25 25 mg
EUR 290
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival.

LOXO-101
B6176-5 5 mg
EUR 128
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival.

CUDC-101
A4092-10 10 mg
EUR 137
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs.

CUDC-101
A4092-200 200 mg
EUR 943
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs.

CUDC-101
A4092-5.1 10 mM (in 1mL DMSO)
EUR 158
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs.

CUDC-101
A4092-50 50 mg
EUR 386
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs.

CUDC-101
A4092-S Evaluation Sample
EUR 81
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs.

ARP 101
A4433-5 5 mg
EUR 334
Description: ARP 101 is a selective MMP-2 inhibitor with IC50 value of 0.81nM.

Sulforhodamine 101
B7762-100 100 mg
EUR 137

Sulforhodamine 101
B7762-250 250 mg
EUR 257

Sulforhodamine 101
B7762-500 500 mg
EUR 390

AS 101
B7830-5 5 mg
EUR 171
Description: Ammonium tri-chloro(dioxoethylene-O,O?-)tellurate (AS-101), an anti?IL-10 compound, is a nontoxic immunomodulator.AS101 (0.43222.5 ?g/ml) decreased IL-10 production in a dose-dependent manner.

Sulforhodamine 101
GT6456-100MG 100 mg
EUR 158

UCF 101
C4437-10 10 mg
EUR 186
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli.

UCF 101
C4437-25 25 mg
EUR 354
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli.

UCF 101
C4437-5 5 mg
EUR 145
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli.

GlyH-101
B1087-10 10 mg
EUR 195
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM.

GlyH-101
B1087-5.1 10 mM (in 1mL DMSO)
EUR 148
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM.

GlyH-101
B1087-50 50 mg
EUR 659
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM.

Trap 101
B7084-10 10 mg
EUR 373

Trap 101
B7084-50 50 mg
EUR 1363

LOXO-101
B2291-25
EUR 631

LOXO-101
B2291-5
EUR 196

KHS-101
B2415-25
EUR 588

KHS-101
B2415-5
EUR 185

CUDC-101
1966-25
EUR 555

CUDC-101
1966-5
EUR 202

AT-101
2380-25
EUR 506

AT-101
2380-5
EUR 164

miRZip-101 anti-miR-101 microRNA construct
MZIP101-PA-1 Bacterial Streak
EUR 684

ECOS 101 (DH5a
FYE607-10VL 100 µl x 10 vials Ask for price

ECOS 101 (DH5a
FYE607-80VL 100 µl x 10 vials Ask for price

ECOS 101 (DH5a
FYE608-10VL 100 µl x 10 vials Ask for price

ECOS 101 (DH5a
FYE608-80VL 100 µl x 10 vials Ask for price

ECOS 101 (DH5a
FYE609-10VL 100 µl x 10 vials Ask for price

ECOS 101 (DH5a
FYE609-80VL 100 µl x 10 vials Ask for price

KHS 101 hydrochloride
B7717-10 10 mg
EUR 318

KHS 101 hydrochloride
B7717-50 50 mg
EUR 1162

LOXO-101 sulfate
B2545-25
EUR 414

LOXO-101 sulfate
B2545-5
EUR 196

Finally, the guidelines for the efficient use of the computation-based LFQ technology and feature selection methods in diabetes proteomics are proposed.In summary, this review provides guidelines for researchers who will engage in proteomics biomarker discovery and by properly applying these proteomic computational advances, more reliable therapeutic targets will be found in the field of diabetes mellitus.